James Fadiman on Microdosing: What 10 Years of Citizen Science Reveals
About This Video
James Fadiman, creator of the Fadiman Protocol and the godfather of systematic microdosing research, reviews what a decade of citizen science self-reporting data reveals about the practice — and where it differs from what controlled trials have found.
Fadiman's dataset is unique: he has collected structured self-reports from thousands of people microdosing under real-world conditions (varying substances, doses, schedules, contexts, and intentions) since around 2010. This naturalistic data captures effects that controlled trials, with their rigid inclusion criteria and standardized conditions, often miss — particularly the heterogeneity of response across different populations and use contexts.
The conversation covers the most consistent findings from citizen science: mood benefits in the 1-3 day following a microdose, reported improvements in focus and creative problem-solving, and a meaningful minority of reports of adverse effects including anxiety and emotional intensification. Fadiman discusses the dose-sensitivity that makes microdosing particularly variable — the difference between a sub-perceptual dose and a low psychedelic dose is often just fractions of a gram, and individual metabolism varies considerably.
He addresses the tension between his citizen science findings and the more mixed controlled trial results (including the 2022 Imperial placebo-controlled study that found significant expectancy effects). Fadiman's response is not defensive dismissal but methodological discussion: what do placebo-controlled trials capture and what do they miss about a practice embedded in daily life?
Key Takeaways
- Ten years of citizen science reports show consistent mood benefits in the 1-3 days following a microdose, with significant individual variability.
- A meaningful minority of microdosers report adverse effects including anxiety and emotional intensification — microdosing is not universally beneficial.
- Dose sensitivity is the primary challenge: the difference between sub-perceptual and low psychedelic doses is small and varies significantly between individuals.
- Controlled trials and naturalistic citizen science capture different phenomena — both are necessary to understand microdosing fully.
- Fadiman's 2024 dataset includes reports from people microdosing for specific applications (ADHD, creativity, emotional regulation) with more differentiated outcomes than general population data.
Dive Deeper
Continue exploring this topic on LearnShrooms: